CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Nima Farzan

Chief Executive Officer, Latigo Biotherapeutics

Search every verified Nima Farzan interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Nima Farzan, chief executive officer of Latigo Biotherapeutics, discussed the company's focus on developing non-opioid pain medications during an interview recorded at the JP Morgan Healthcare Conference in January 2025. He described Latigo's work on selective inhibitors targeting NAV 1.8 sodium channels, which are involved in pain signal transmission, as a potential way to provide pain relief without the addiction risks and side effects associated with traditional opioids. Farzan stated that pain management has been "overdue for an overhaul" and noted that the opioid crisis has been a significant societal challenge. Farzan, who joined Latigo about six months prior to the interview, said his background includes leading groups and marketing at Novartis before moving into biotech and venture capital. He described his expertise as transitioning companies from discovery-focused to development-focused stages, and said Latigo was primarily a discovery team when he arrived. He also commented on broader industry trends, suggesting that R&D investment has shifted away from larger opportunities toward rare diseases, and that the pendulum may swing back toward areas like obesity and other large markets.

Recent appearances

  • Are we there yet? Surviving and thriving in the never-ending biotech downturn

    June 04, 2026 · 📺 BioSpace

    The rumors of biotech’s return have been greatly exaggerated. Despite some M&A sparks, a handful of mega fundraises and a trickle of IPOs, the biotech industry continues to climb out of a multi-year down period. So how does a company thrive in this environment? BioSpace sits down with four NextGen companies doing just that, to hear about ways they are defying the odds to churn out clinical data that may finally provide the industry with a ladder out. Panelists Dannielle Appelhans | CEO | COUR Pharmaceuticals Dannielle Appelhans is leading growth at COUR Pharmaceuticals as the company advanc…

    Watch on YouTube ↗

  • BoB@JPM: Nima Farzan, Latigo Biotherapeutics

    March 23, 2025 · 📺 Life Science Connect

    In this final installment of our episodes recorded and filmed on-site at the JP Morgan Healthcare Conference, Nima Farzan, CEO of Latigo Biotherapeutics, shares his company's mission to change the pain management paradigm by way of novel, non-opioid medications that target NAV 1.8 sodium channels involved in pain signal transmission. It's a timely and important conversation that explores how these selective inhibitors could provide effective pain relief without the addiction risks and side effects of traditional opioids. In addition to the social and medical implications of Latigo's work, we d…

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →